This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

EDRA L. SPILMAN, Ph.D.; DANIEL W. BADAL, M.D.

AMA Arch Gen Psychiatry 1960;2(5):545-547.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Recent studies on the mechanisms of action of reserpine and various amine oxidase inhibitors suggest that the enzyme amine oxidase plays a significant role in regulating the concentration of tissue catechol amine.^1-6 Reserpine effects an irreversible release of bound serotonin and arterenol (noradrenalin). These compounds may be oxidized by amine oxidase or excreted, and, as a result, tissue catechol amine concentrations decrease.⁷ On the other hand, the administration of amine oxidase inhibitors, such as iproniazid (isonicotinylisopropylhydrazine) and pheniprazine (β-phenylisopropylhydrazine) causes an increase in brain serotonin,^8,9 which is particularly evident with the concurrent administration of 5-hydroxytryptophan.^4,9

It has been further reported that iproniazid, pheniprazine, and other amine oxidase inhibitors alleviate some of the symptoms of certain mental depressions.¹⁴ This function has been attributed to their property of inhibiting amine oxidase. A number of drugs of similar . . . [Full Text PDF of this Article]

Author Affiliations
Cleveland

Western Reserve University School of Medicine.

Footnotes
Submitted for publication Jan. 14, 1960.

This work was sponsored by the National Institutes of Health, Mental Health Division, Grant No. M-2733 Cl.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?